glp-1 compounding fda The FDA's Crackdown Continues: What to Know FDA Moves to Close a

"Chronic Limb-Threatening Ischemia (CLTI) Vascular Cures"

* Cases of convulsions have been reported in patients, with or without a history of seizure activity, who have received oral or intravenous L-carnitine

An omics-based framework for assessing the health risk of antimicrobial resistance genes

If approved, we are ready to offer a convenient, once-daily pill that can be scaled globally, removing barriers and redefining how obesity is treated around the world, Kenneth Custer, PhD, Lilly executive vice president and president of Lilly Cardiometabolic Health, said in an August 26 statement

The market is likely to favor credible protein-and-fiber propositions with straightforward communication

Inside Biotech: Structure Therapeutics jolts oral GLP-1 race with mid-stage data Published: 01:39 17 Mar 2026 EDT The next phase of the weight-loss drug boom is taking shape and its no longer just about who has the most effective injectable